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Chemokines are best known as signaling proteins in the immune system. Recently
however, a large number of human chemokines have been shown to exert direct
antimicrobial activity. This moonlighting activity appears to be related to the net
high positive charge of these immune signaling proteins. Chemokines can be divided
into distinct structural elements and some of these have been studied as isolated
peptide fragments that can have their own antimicrobial activity. Such peptides often
encompass the α-helical region found at the C-terminal end of the parent chemokines,
which, similar to other antimicrobial peptides, adopt a well-defined membrane-bound
amphipathic structure. Because of their relatively small size, intact chemokines can
be studied effectively by NMR spectroscopy to examine their structures in solution.
In addition, NMR relaxation experiments of intact chemokines can provide detailed
information about the intrinsic dynamic behavior; such analyses have helped for example
to understand the activity of TC-1, an antimicrobial variant of CXCL7/NAP-2. With
chemokine dimerization and oligomerization influencing their functional properties, the use
of NMR diffusion experiments can provide information about monomer-dimer equilibria
in solution. Furthermore, NMR chemical shift perturbation experiments can be used to
map out the interface between self-associating subunits. Moreover, the unusual case of
XCL1/lymphotactin presents a chemokine that can interconvert between two distinct folds
in solution, both of which have been elucidated. Finally, recent advances have allowed for
the determination of the structures of chemokines in complex with glycosaminoglycans, a
process that could interfere with their antimicrobial activity. Taken together, these studies
highlight several different structural facets that contribute to the way in which chemokines
exert their direct microbicidal actions.
Keywords: chemokine, antimicrobial peptide, chemokine structure, chemokine oligomerization,
glycosaminoglycan
INTRODUCTION
Chemokines are a superfamily of small globular proteins
(8–12 kDa) that play essential roles in both innate and adap-
tive immunity (Esche et al., 2005; Allen et al., 2007). These
∼70 residue proteins are responsible for the trafficking and
activation of all leukocytes through interactions with G-protein-
coupled chemokine receptors. Additionally, chemokine-mediated
cell migration is involved in processes such as tissue development,
Abbreviations: AMP, antimicrobial peptide; BRAK, breast and kidney-expressed
chemokine; CCL, CC chemokine ligand; CD, circular dichroism; CXCL, CXC
chemokine ligand; CXCR, CXC chemokine receptor; CTAP-3, connective tissue-
activating peptide 3; FAF, F. magna adhesion factor; GAG, glycosaminoglycan;
GCP-2, granulocyte chemotactic protein 2; HBD, human β-defensins; His-5,
histatin-5; HNP, human neutrophil protein; IL-8, interleukin-8; IP-10, inter-
feron γ-induced protein-10; I-TAC, interferon-inducible T-cell α chemoattractant;
mCCL, murine CCL; MCP, monocyte chemoattractant protein; MIG, monokine
induced by γ-interferon; MIP-3α, macrophage-inflammatory protein-3α; MRSA,
methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; NAP-2,
neutrophil-activating peptide 2; NMR, nuclear magnetic resonance; NOE, nuclear
Overhauser effect; PBP, platelet basic protein; PF-4, platelet factor 4; RANTES,
regulated-upon activation, normal T-cell expressed, and secreted; SDF-1α, stromal
cell-derived factor-1α; SIC, streptococcal inhibitor of complement; SPA, S. aureus
protein A; TC-1, thrombocidin-1.
angiogenesis, cancer progression, and infection (Kiefer and
Siekmann, 2011; Lehner et al., 2011; Balkwill, 2012).
In order to achieve tight control over the biological activ-
ities of the diverse types of leukocytes, there are close to 50
human chemokines that can activate 19 different transmembrane
receptors (Allen et al., 2007). Chemokines are usually classified
into four categories according to the pattern of several con-
served disulfide-bonded cysteine residues near their N-terminal
regions: CC, CXC, C, and CX3C. Despite large differences in their
amino acid sequences, the three-dimensional monomeric struc-
tures of chemokine are remarkably similar to each other. They
are composed of the following secondary structure elements: an
extended N-terminal loop that is important for receptor activa-
tion, a central three-stranded antiparallel β-sheet that provides a
stable scaffold, and a C-terminal α-helix that stabilizes the overall
structure by folding over the small β-sheet (Figure 1) (Fernandez
and Lolis, 2002; Allen et al., 2007). Chemokine activity can to
some extent be regulated by post-translational proteolytic pro-
cessing and by chemical modifications that can take place under
different physiological and pathological conditions (Wolf et al.,
2008; Mortier et al., 2011). Further regulation can occur through
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FIGURE 1 | Topology of a typical chemokine. The N-terminal loop, which
is responsible for receptor recognition, is restrained by two disulfide bonds
(in yellow). This is followed by a short turn of a 310 helix that leads to a
three-stranded antiparallel β-sheet. The C-terminal α-helix folds over the
β-sheet and helps to stabilize the overall tertiary structure.
modulation of the oligomerization state as chemokines may
form homodimers, heterodimers, tetramers, or higher oligomers
under various physiological conditions (Weber andKoenen, 2006;
Salanga and Handel, 2011). Chemokines also interact with gly-
cosaminoglycans (GAGs), which are themselves a heterogeneous
group of polysaccharides that are a part of extracellular proteo-
glycans, and these interactions further modulate the function,
oligomerization state, and localization of chemokines (Proudfoot,
2006).
Following the initial discovery of an antimicrobial chemokine
by Dankert and coworkers (Krijgsveld et al., 2000), the majority
of human chemokines are now known to play a role as direct
broad-range microbicidal agents, an activity that is otherwise
primarily associated with antimicrobial peptides (AMPs) (Arias
et al., 2012). AMPs are not only another class of bactericidal
or bacteriostatic molecules secreted by the innate immune sys-
tem, but they are also major players in host defense systems
(Brown andHancock, 2006). Thus far, well over a thousand AMPs
have been identified (Seshadri Sundararajan et al., 2012). Most
AMPs are capable of selectively causing disruptions in the bacte-
rial membrane integrity (Haney et al., 2010), however, the list of
possible mechanisms is growing and a peptide may have multiple
molecular targets to achieve its antimicrobial activities (Nicolas,
2009; Nguyen et al., 2011a). Although AMPs are often classified in
broad structural terms as α-helical, β-sheet or extended, the vast
majority display an amphipathic structure in their membrane-
bound form that encompasses a hydrophobic and a positively
charged surface. Additionally, a few mammalian AMPs have been
shown to induce chemotaxis thereby emulating the action of
chemokines (Yang et al., 1999; Bowdish et al., 2005; Auvynet et al.,
2008).
In a comprehensive study where 30 human chemokines were
assayed for bactericidal activity, 18 members were found to
have activity against both Escherichia coli and Staphylococcus
aureus (Yang et al., 2003). Most chemokines generally have high
isoelectric points around 9.0 or higher, and the high abundance
of Arg and Lys residues is thought to be responsible for the
antimicrobial activity. Surveying the current literature, only 3
out of 43 chemokines do not have any antimicrobial activ-
ity reported, while four others have yet to be assayed (Yung
et al., 2011; Arias et al., 2012; Burkhardt et al., 2012). Of the
non-antimicrobial chemokines [CC chemokine ligand 3 (CCL3),
CCL16, and CCL24], two have particularly high pI’s (4.48, 9.86,
and 10.76, respectively), therefore overall cationicity cannot be
considered as the single reliable predictor of antimicrobial activ-
ity. Nevertheless, the high number of antimicrobial chemokines
conflicts with some of the negative results reported in the initial
study by Yang et al. (2003). This can be reflective of variations
in assay media and the different bacterial strains used by various
research groups and, occasionally, the variant of the chemokine
being studied. In many of the studies mentioned in this article, a
chemokine that is considered as non-antimicrobial is only cate-
gorized as such in direct testing comparisons to a chemokine that
demonstrates high antimicrobial activity, although they may both
be active in another assay. Assays are often performed in low salt
media and many chemokines can lose their activity at increased
salt concentrations (Collin et al., 2008), however, this is not always
the case. For example, CCL4 has a low pI of 4.47 and is not antimi-
crobial in 10mM NaCl, but it gains growth inhibitory activity
against methicillin-sensitive S. aureus (MSSA) and methicillin-
resistant S. aureus (MRSA) at a physiological concentration of
137mMNaCl (Yung et al., 2011). Additionally, some chemokines
have been assayed for antimicrobial activity in a biomatrix that
resembles human blood (Yeaman et al., 2007).
Due to their relatively small size, the structures of chemokines
can be studied by nuclear magnetic resonance (NMR) spec-
troscopy in atomic detail, starting with the first chemokine
structure reported for CXCL-8/IL-8 (CXC motif chemokine
8/interleukin-8), which was studied as a dimer in solution (Clore
et al., 1990). In addition to obtaining detailed three-dimensional
structure information, different NMR techniques can be used
to study chemokines with regard to their local dynamics, to
map out the interfaces between subunits of dimers or higher
oligomers, or to study their interactions with GAGs. Although it
is outside of the scope of this article, significant advances have
also been made recently in the characterization of chemokine-
receptor interactions by solution NMR methods (Kofuku et al.,
2009; Yoshiura et al., 2010). Here, we will evaluate the various
structural properties of chemokines (summarized in Table 1) in
an attempt to explain their “moonlighting” function as direct
antimicrobial agents.
CHEMOKINE-DERIVED ANTIMICROBIAL FRAGMENTS
The chemokine CCL20/MIP-3α (macrophage-inflammatory
protein-3α) is functionally similar to the β-defensin AMPs as
they can both activate the same chemokine receptor, CCR6 (Yang
et al., 1999), and they are both highly antimicrobial. Structurally,
these proteins have an antiparallel three-stranded β-sheet in
common. It has been suggested that the host defense peptide
groups of chemokines and cysteine-containing AMPs such as the
defensins may share a unifying structural signature termed the
γ-core motif (Yount et al., 2007). CCL20 can be hydrolyzed at
positions 52 or 55 by cathepsin D, a protease involved in tumor
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Table 1 | Summary of antimicrobial chemokines discussed in this review.
Chemokine Classical
nomenclature
Structural aspects discussed References
XCL1 Lymphotactin Conformational inter-conversion Tuinstra et al., 2008
CCL5 RANTES Oligomerization Wang et al., 2011
CCL13 MCP-4 Antimicrobial fragment (α-helix) Martinez-Becerra et al., 2007
CCL20 MIP-3α Antimicrobial fragment (α-helix)
C-terminal processing
Dimerization
Hasan et al., 2006; Chan et al., 2008
CCL28 CCL28 Disufide reduction
Antifungal fragment (α-helix)
Mutational studies
Hieshima et al., 2003; Liu and Wilson, 2010
CXCL4 PF-4 Antimicrobial fragment (α-helix)
Heterodimerization
Tang et al., 2002; Yeaman et al., 2007
CXCL6 GCP-2 Antimicrobial fragment (β-sheet)
Membrane-induced conformational change
Linge et al., 2008
CXCL7 PBP, CTAP-3, NAP-2,
TC-1








Krijgsveld et al., 2000; Tang et al., 2002;
Kwakman et al., 2011; Nguyen et al., 2011b
CXCL8 IL-8 Antimicrobial fragment (α-helix)
GAG interactions
Bjorstad et al., 2005; Pichert et al., 2012
CXCL9 MIG Antimicrobial fragment (α-helix)
Disulfide reduction
Egesten et al., 2007, 2009
CXCL10 IP-10 C-terminal processing Hensbergen et al., 2004
CXCL12 SDF-1α Oligomerization
GAG interactions
Murphy et al., 2010; Laguri et al., 2011
progression (Hasan et al., 2006). The C-terminal fragment,
comprising the α-helix of the intact protein, retains antimicrobial
activity while the N-terminal portion (residues 1–52) that
includes the entire β-sheet is inactive. The C-terminal peptide of
CCL20 is very cationic and has similar properties compared to
canonical α-helical AMPs such as magainin (Haney et al., 2009).
It is unstructured in aqueous solution and requires a membra-
nous environment to fold into a well-defined amphipathic helix
that resembles its conformation within the parent chemokine.
This potent chemokine-derived AMP preferentially disrupts
anionic model membranes over zwitterionic ones (Nguyen
et al., 2010a). These two model membranes are frequently used
to represent bacterial and eukaryotic membranes, respectively
(Lohner, 2001). Bacterial membranes are rich in phospholipids
with phosphatidylglycerol headgroups, which are negatively
charged, while the outer leaflet of eukaryotic cells is usually
made up of phosphatidylcholine headgroups, which have no net
charge.
Peptides covering the entire amino acid sequences of CCL13
and mammalian CXCL4/PF-4 (platelet factor 4) were assayed
for antimicrobial activity (Martinez-Becerra et al., 2007; Yeaman
et al., 2007). In both cases, the most active fragments covered the
α-helices of the chemokines and these had comparable potency
to the native proteins. Similar to the CCL20-derived peptide,
these peptides include many cationic residues and they seem to
permeabilize bacterial membranes to cause notable morphologi-
cal changes. Interestingly, in the case of CXCL8, the C-terminal
α-helix is similar in sequence to a bactericidal peptide from
Helicobacter pylori (Bjorstad et al., 2005). The peptide corre-
sponding to this region can be released via acid hydrolysis and
possesses antibacterial activity that is absent in full-length IL-8.
This activity increases at lower pH levels and is attenuated by high
salt concentrations. The structure of the peptide bound to SDS
micelles was solved using NMR spectroscopy, showing an amphi-
pathic helix where the cationic face, composed of five Lys or Arg
side chains, is partially disrupted by the presence of three nega-
tively charged Glu side chains (Bourbigot et al., 2009). Solid-state
NMR experiments and functional leakage assays indicate that this
peptidemay not be able to cause significantmembrane disruption
(Bourbigot et al., 2009; Nguyen et al., 2010a).
However, the antimicrobial activity of chemokines is not
always concentrated in the C-terminal helical region. When sepa-
rated, the N-terminal 50 residues of CXCL6/GCP-2 (granulocyte
chemotactic protein 2) is ten times more bactericidal than its 19
C-terminal residues despite the latter having a higher pI (Linge
et al., 2008). However, neither peptide is as active as the parent
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chemokine. The β-sheet containing N-terminal fragment disturbs
anionic membranes to cause liposome leakage levels similar to
intact CXCL6 while the C-terminal peptide is not membrane
disruptive (Linge et al., 2008).
A set of overlapping 15-mer peptides covering the amino
acid sequence of TC-1 (CXCL7/thrombocidin-1), a bacterici-
dal chemokine released from thrombin-activated blood platelet
granules, have been assayed for antimicrobial activity (Kwakman
et al., 2011). While the peptide corresponding to the C-terminal
α-helix displays mild activity, the most potent peptide corre-
sponded to residues 3–17 of TC-1, which are situated in the
extended N-terminal fragment and the 310 helical turn preceding
the β-sheet. This was unexpected, given that this peptide is not as
cationic nor is it more hydrophobic than the 15-residue sequence
encompassing the C-terminal α-helix. Interestingly, the peptide
has a distinct activity profile compared to TC-1: while they are
both equally potent against Bacillus subtilis, the peptide is more
antifungal against Cryptococcus neoformans, and intact TC-1 is
more active against E. coli and S. aureus. This suggests that the
peptide and intact TC-1 may employ different mechanism(s) of
antibacterial action. NMR spectroscopy experiments show that,
in a membranous environment, the N-terminal peptide folds into
an extended amphipathic conformation and does not resemble
the α-helix that is normally associated with many AMPs of this
size (Figure 2A). In the native TC-1 chemokine, the region rep-
resented by the peptide has two disulfide bonds that restrain it to
the rest of the protein.
STRUCTURAL DETERMINANTS FOR ANTIMICROBIAL
ACTIVITY
TC-1 is found in platelet α-granules and it is an antimicro-
bial derivative of NAP-2 (CXCL7/neutrophil-activating peptide
2) that has been truncated by two C-terminal amino acids,
Ala69, and Asp70 (Krijgsveld et al., 2000). NAP-2 itself is the
mature product of several N-terminal truncations from PBP
(CXCL7/platelet basic protein) (Brandt et al., 2000). Peptides
encompassing the α-helical regions of TC-1 and NAP-2 are
inactive as antimicrobials, however, their structures solved in a
membrane-mimetic environment may help to explain the differ-
ence in the activity of these chemokines (Nguyen et al., 2010a).
NAP-2 contains four negative charges in its last five residues, and
this tail folds back onto the α-helix via electrostatic interactions.
This would effectively mask some of NAP-2’s cationic surface and
would reduce its affinity for negatively charged bacterial mem-
brane surfaces. The last four residues of NAP-2 were not included
in the X-ray crystal structure due to poorly defined electron
density in this region (Malkowski et al., 1995). NMR relaxation
experiments reveal that, although the last five residues are overall
FIGURE 2 | Different ways in which the structure of the
antimicrobial chemokine thrombocidin-1 (CXCL7/TC-1) has been
studied by NMR spectroscopy. (A) Membrane-bound conformations
of two peptides from different regions of TC-1 showing some
antimicrobial activity. (B) Model-fitted order parameters from NMR
relaxation experiments comparing the local dynamics of TC-1 and
NAP-2. The C-terminal tail of NAP-2 becomes less flexible in its final
residues, in contrast to TC-1. (C) Electrostatic surface diagram showing
the large “positive patch” of TC-1. (D) Electrostatic surface diagram
showing the extension of the positive patch created through TC-1
dimerization. Panels (B) and (D) reprinted with permission from
Nguyen et al. (2011b).
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quite flexible compared to the rest of NAP-2, the final two residues
becomemoremotionally restricted than the residues immediately
preceding them (Figure 2B) (Nguyen et al., 2011b). By compari-
son, the TC-1 backbone continually increases in flexibility toward
the end of its sequence and the C-terminus was not seen to fold
back over the α-helix in the corresponding peptide. Two addi-
tional natural isoforms featuring further C-terminal truncations,
removing the last four and seven residues of NAP-2, respectively,
have been identified previously (Ehlert et al., 1998). These vari-
ants are more potent as neutrophil activators and the removal
of more negative charges would be expected to further improve
the antimicrobial activity of TC-1, although this has not yet
been tested experimentally. The functional activation of NAP-2
in platelets represents a unique case because no other chemokine
post-translational processing events have been found to increase
the antimicrobial activity (Wolf et al., 2008). In other instances
where proteolytic cleavage occurs at the C-terminus, positively
charged residues are lost from chemokines that are alreadymicro-
bicidal (Davis et al., 2005; Mortier et al., 2008; Denis et al., 2012).
For example, CXCL10/IP-10 (interferon γ-induced protein-10)
retains its activities against E. coli and Listeria monocytogeneses in
spite of the loss of two positively charged residues, in a reaction
that is catalyzed by the proprotein convertase furin (Hensbergen
et al., 2004).
It is possible that the longer C-terminus of NAP-2 can also
make electrostatic contacts with other positively charged residues
beyond the α-helix. Upon examination of the charge distribu-
tion of the TC-1 surface, there is a “positive patch” on the protein
surface that becomes evident (Figure 2C). This area features five
Lys/Arg side chains from the α-helix and also includes Lys17 in
the turn between the N-terminal segment and the first β-strand
and three residues (Lys41, Arg44, and Lys45) in the turn between
the second and third β-strands (Kwakman et al., 2011). Lys-
substituted mutants to augment the positive patch have shown
that the inhibitory activity of TC-1 against B. subtilis, S. aureus,
and E. coli can be improved upon. However, these substitutions
either had little effect on or abolished the anti-fungal activity.
The positive patch of TC-1 may undergo some rearrangement
given that, upon binding to negatively charged membranes, the
structure of TC-1 takes on a higher α-helical content as mea-
sured by circular dichroism (CD) spectroscopy (Kwakman et al.,
2011). The killing kinetics of TC-1 show that it acts within 10min
(Krijgsveld et al., 2000), which is fast enough to suggest that it
may perturb the bacterial membrane. However, TC-1 is inca-
pable of dissipating the membrane potential of a Lactococcus
species (Krijgsveld et al., 2000). CD spectra of intact CXCL6 show
that this chemokine also becomes more α-helical upon binding
to a membrane surface and, unlike TC-1, CXCL6 is membrane
disruptive (Linge et al., 2008). The determination of a high res-
olution structure of a membrane-bound chemokine by NMR
spectroscopy would therefore be of great help in understanding
their antimicrobial behavior.
The disulfide reduced form of TC-1 is almost equally effec-
tive as an antimicrobial as native TC-1 and it adopts a simi-
lar membrane-induced structure despite the loss of secondary
and tertiary structure in aqueous solution (Kwakman et al.,
2011). Although disulfide bonds are usually essential for retaining
chemokine structure in aqueous solution and for maintaining
their cell signaling functions (Rajagopalan and Rajarathnam,
2006), linearized analogs of chemokines such as CXCL9/MIG
(monokine-induced by γ-interferon) and CCL28 also retain
antimicrobial activity (Egesten et al., 2009; Liu andWilson, 2010).
Disulfide bonds are not required for the activity of several AMPs
either (Ramamoorthy et al., 2006; Dawson and Liu, 2010); in
fact, the human β-defensins-1 and -3 (HBD1 and HBD3) become
more active upon linearization (Wu et al., 2003; Schroeder et al.,
2011). However, in vivo, linear AMPs can be easily degraded
in human serum and folded chemokines would be more stable
under these conditions (Nguyen et al., 2010b).
CCL28 is a broad-spectrum antimicrobial chemokine that is
expressed in mucosal tissues and it can be recovered in high
amounts from saliva and milk (Hieshima et al., 2003). The three
dimensional structure of the 108-residue long CCL28 has yet
to be determined, however, the solution structure of human
CCL27, a related 88-residue long chemokine, can provide some
information (Jansma et al., 2010). CCL27 has the typical 3-
stranded β-sheet followed by an α-helix that runs from Pro59
to Arg70, after which the remaining 18 residues are disordered.
The C-terminal region of CCL28 is an important determinant for
its antimicrobial activity. The corresponding disordered portion
beyond the α-helix in CCL28 would encompass 26 residues, and
this region has high sequence similarity to histatin-5 (His-5). His-
5 is an antifungal His-rich peptide produced in saliva (Tsai and
Bobek, 1998). In aqueous solution, His-5 is unstructured and in
the presence of a membranous environment, an α-helical struc-
ture is induced (Raj et al., 1998). However, it should be noted that
His-5 seems to act intracellularly following membrane transloca-
tion (Jang et al., 2010). A CCL28-derived peptide composed of
the His-5-like sequence loses activity against five different bacte-
rial strains compared to the parent CCL28 chemokine and, like
His-5, it is mostly an antifungal agent (Hieshima et al., 2003).
His-5 is internalized into C. albicans cells following translocation.
However, its killing mechanism as well as the role of its ability
to bind divalent cations such as Zn2+ and Cu2+ remain unclear
(Gusman et al., 2001; Jang et al., 2010). Whether the His-rich
tail of CCL28 can similarly coordinate metal ions remains to be
determined.
Truncation mutants of murine CCL28 (mCCL28) indicate
that, although optimal activity is retained only in the full
chemokine, it can tolerate the loss of 18 residues in its C-terminus
before it loses significant bactericidal activity (Liu and Wilson,
2010). These authors also identified a sequence at positions
85–89 (RKDRK) that is essential for the antimicrobial activ-
ity. However, in amino acid sequence alignments, this particular
motif is noticeably absent in mice and many other mammals.
The corresponding motif in CCL28 from chimpanzees, monkeys
and humans (KRNSN) loses one positive charge, yet the latter
homolog is more antimicrobial than mCCL28 (Hieshima et al.,
2003). The C-terminal half of mCCL28, comprised of the puta-
tive α-helix and the long disordered tail, when assayed by itself
is not as microbicidal as full-length mCCL28 (Liu and Wilson,
2010). Because mCCL27 is a non-antimicrobial chemokine that
has high sequence homology to mCCL28, a construct was made
combining the N-terminal half of mCCL27 and the C-terminal
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half of mCCL28, and this chimeric protein was able to recover
the full activities of mCCL28. The C-terminal region of mCCL28
was also combined with the N-terminal half of mCCL5, an unre-
lated chemokine with low antimicrobial activity, and this led to
an interesting activity profile. Compared tomCCL28, the chimera
had diminished activity against Grampositive S. aureus, but it had
retained full activity against Gram negative P. aeruginosa (Liu and
Wilson, 2010). Therefore, the two halves of mCCL28 contribute
in different proportions to its activity against different species.
THE ROLE OF DIMERIZATION AND OLIGOMERIZATION
3D structures of chemokines are often solved by X-ray crystallog-
raphy or by NMR spectroscopy as dimers or tetramers (Figure 2).
This may be due to the high protein concentrations required
for such studies. The oligomerization dissociation constants of
chemokines are usually in the micromolar range which would
therefore lead to expectations that they are monomeric in serum
where their concentrations are typically in the nanomolar range
(Fernandez and Lolis, 2002). However, the self-association equi-
libria can be shifted toward the dimerization state by changes in
pH, salt concentration and the presence of anions such as phos-
phate, sulfate and by the presence of GAGs (Mayo and Chen,
1989; Veldkamp et al., 2005). Pulsed field gradient NMR exper-
iments measuring molecular diffusion rates can give indications
as to the oligomerization state of a chemokine under different
conditions. In CXCL12/SDF-1α (stromal cell-derived factor-1α)
and CCL20, the dimerization is influenced by the protonation
state of specific histidine residues, His28 in the first β-strand
of CXCL12 and His40 in the second β-strand of CCL20. At
pH values below the pKa of these residues, the charged pro-
tonated His residues repel each other and this in turn breaks
the intermolecular contacts and the monomeric state is favored
(Veldkamp et al., 2005; Chan et al., 2008). In contrast, interactions
with highly negatively charged GAGs usually promote dimeriza-
tion and may help in establishing chemokine gradients toward
sites of infection (Lortat-Jacob, 2009). Receptor activation can
be demonstrated for most monomeric chemokines in vitro, how-
ever, oligomeric forms are also functionally important (Salanga
and Handel, 2011). For example, 15N-1H heteronuclear nuclear
Overhauser effect (NOE) and chemical shift perturbation map-
ping from NMR experiments show that the monomeric form of
CXCL12makes specific contacts with the receptor CXCR4 that are
lost after it dimerizes (Drury et al., 2011). However, both forms
interact with CXCR4 and cause distinct biological events in col-
orectal carcinoma cells. The receptor is a constitutive homodimer
in vivo, therefore the state of its single- or double-ligand occu-
pancy can lead to the activation of different intracellular signaling
cascades.
The oligomerization of AMPs is thought to markedly influ-
ence their activity, especially concerning membrane disruption
(Mihajlovic and Lazaridis, 2010). Disulfide-linked dimeric ana-
logues of α-helical peptides such as magainin usually have
improved activity (Tencza et al., 1999; Dempsey et al., 2003),
while β-sheet peptides such as the defensin human neutrophil
protein-1 (HNP-1) and protegrin-1 have to dimerize to form
membrane pores, the latter assembling into a β-barrel-like pore
(Mani et al., 2006; Zhang et al., 2010). Furthermore, the higher
tendency of HBD-3 to dimerize compared to HBD-1 and HBD-2
is thought to contribute to its higher overall activity and to its
salt-resistant antimicrobial properties (Schibli et al., 2002).
It therefore seems likely that the oligomerization of
chemokines would also enhance their antimicrobial poten-
tial. The dimerization of chemokines may extend their cationic
surface across a larger continuous area to facilitate interactions
with the negatively charged bacterial surfaces. Apart from the
unmasking of the positive patch from the shorter tail of TC-1
as discussed above, this platelet chemokine also has a higher
tendency to dimerize compared to NAP-2 and this could further
contribute to the differences in their activities (Figure 2D)
(Nguyen et al., 2011b). Amongst the closely related monocyte
chemoattractant proteins (CCL2/MCP-1, CCL8/MCP-2, and
CCL7/MCP-3), CCL7 has the lowest propensity to form dimers
and, despite having the highest pI among them, it also has the
weakest antimicrobial activity (Kim et al., 1996). However, the
tendency to dimerize is not always a requirement for microbicidal
chemokines. For example, CCL1/I-309 and CCL15 are known to
be monomeric at concentrations up to 2mM yet they do display
some antimicrobial activity (Sticht et al., 1999; Keizer et al.,
2000).
Most CC chemokines self-associate through the formation of
a small antiparallel β-sheet between the N-terminal residues of
both subunits, resulting in an elongated structure (Figure 3).
Generally, CXC chemokine dimers are more compact with the
main contacts formed between the first β-strands of each sub-
unit and a small reorientation of the α-helices (Chan et al.,
FIGURE 3 | Levels of oligomerization in chemokines. A typical
chemokine monomeric unit is shown at the top (CCL20; PDB ID 2JYO). The
CC-type dimer is formed from contacts between the N-terminal fragments
of each subunit to create an elongated shape (CCL2 homodimer; PDB ID
1DOM). The CXC-type dimer is created by the continuation of the β-sheets
via their first strands and a small reorientation of the α-helices, running
anti-parallel to each other (CXCL8; PDB ID 1IL8). Heterodimerization is also
possible, modeled here from two subunits of CXCL8 and PF-4 (PDB ID 1IL8
and 1RHP, respectively). The common tetramer organization of chemokines
is shown for CXCL4, colored to highlight their configuration as a dimer of
dimers (PDB ID 1RHP). A less common form of higher oligomerization is
represented by CCL5 in a linear polymeric chain of repeating dimer units
(PDB ID 2L9H).
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2008; Gandhi andMancera, 2011). Given these two main patterns
of quaternary structure, a few chemokine pairs have a prefer-
ence for heterodimerization over homodimerization, which can
add another layer to the regulation of their biological functions
(Nesmelova et al., 2005; Weber and Koenen, 2006). Such interac-
tions may also promote their antimicrobial activities, and the syn-
ergistic bactericidal effect of the platelet chemokines CXCL4 and
CTAP-3 (CXCL7/connective tissue-activating peptide 3) against
E. coli are likely influenced by their heterodimerization (Tang
et al., 2002; Nesmelova et al., 2008).
XCL1/Lymphotactin is a rather unique case where the
chemokine structure rapidly interconverts between two unrelated
conformations in vivo (Figure 4) (Tuinstra et al., 2008). These
states can be stabilized by carefully controlling the temperature
and salt concentration for structure determination by NMR spec-
troscopy. In the low temperature high salt condition, the typical
chemokine fold of a three-stranded β-sheet followed by an α-helix
dominates as a monomer. This form is functional for receptor
binding, but does not interact with GAGs. In the high tempera-
ture low salt condition, XCL1 rearranges itself into a novel protein
fold of a four-stranded antiparallel β-sheet sandwiched with
another subunit as a head-to-tail dimer. Using isotope-filtered
NOESY NMR experiments on a mixture of labeled and unlabeled
XCL1, intermolecular contacts could be observed to identify the
dimer interface. This alternate conformation does not interact
with the XCR1 receptor. Instead, it clusters the acidic residues of
the monomer subunits to one end of the dimer interface, leav-
ing a large surface of positively charges at the opposite end that
can interact with GAGs or bacterial membranes (Tuinstra et al.,
2008).
Higher order homo-oligomers of chemokines often take the
shape of a globular complex. For example, the tetramers of
NAP-2 and CXCL10 have been described as dimers of β-sheet
dimers (Malkowski et al., 1995; Swaminathan et al., 2003). For
CCL5, however, a different form of oligomerization has been
observed through the integrated use of various structural tech-
niques (Wang et al., 2011). The relative orientations of the
monomer subunits were determined by measuring NMR residual
dipolar couplings, while the interfacial contacts were identified
by NMR cross-saturation and mass spectrometry footprinting
FIGURE 4 | The two structural folds adopted by XCL1 that co-exist in
equilibrium with each other under physiological conditions (Tuinstra
et al., 2008). On the left is the typical chemokine fold of lymphotactin and
on the right is the alternate all β-sheet conformation which readily dimerizes
to form a head-to-tail β-sheet sandwich (PDB ID 1J9O and 2JP1,
respectively).
experiments. Also, small angle X-ray scattering results were used
to restrict the overall shape of the oligomer. The final model of
the aggregate shows repeating units of CCL5 dimers assembling
into a linear polymeric chain that may be able to accommodate
simultaneous interactions with the receptor as well as with a long
GAG molecule. X-ray crystallography data show that similar lin-
ear structures can be formed by CCL3/MIP-1α, CCL4/MIP-1β,
and CXCL12 (Murphy et al., 2010; Ren et al., 2010). While CCL3
and CCL4 have little to no antimicrobial activity due to their low
net charge at neutral pH, the polymerization of the antimicrobial
CXCL12 and CCL5 chemokines may make them less susceptible
to secreted bacterial proteases.
INTERACTIONSWITH GLYCOSAMINOGLYCANS AND OTHER
MODULATORY MOLECULES
Glycosaminoglycans are heterogeneous unbranched polysaccha-
rides with high charge densities, usually coming from sulfate or
carboxylate groups that are present in the extracellular matrix
as proteoglycan attachments or as freely circulating molecules.
GAG binding to chemokines typically promotes their oligomer-
ization and their retention on cell surfaces, which can create
high local chemokine concentrations at sites of infection to exert
their antimicrobial effects (Proudfoot, 2006). On the other hand,
such interactions should diminish the activity of microbicidal
chemokines given that the negatively-charged GAGs and bacterial
membrane surfaces would compete for the same cationic surfaces
on the proteins. In fact, secreted proteinases from the pathogens
P. aeruginosa, E. faecalis, and S. pyogenes can digest proteoglycans,
thereby releasing dermatan sulfate which can bind to and inacti-
vate the bactericidal activity of HNP-1 (Schmidtchen et al., 2001).
Similar interactions are also possible with HBD-2, where the type
of GAG involved in the interaction can promote the presence of
either the monomeric or the dimeric form of the peptide (Seo
et al., 2010).
A common sequence recognition motif for GAGs such as hep-
aran sulfate or heparin is BBXB, where B is a basic amino acid
(Hileman et al., 1998). Interacting residues have been identi-
fied via mutational studies, and the location of this motif varies
between different chemokines. Binding sites appear at the turn
before the first β-strand in CXC12; the turn between the sec-
ond and third strands in CCL7, CCL3, CCL4, and CCL5; and
the α-helix in CXCL8 (Salanga and Handel, 2011). The heparin
binding interface for CXCL11/I-TAC (interferon-inducible T-cell
α chemoattractant) also involves a cluster of positively charged
residues at the C-terminal helix (57KSKQAR62), however, Lys17
is also an important residue (Severin et al., 2010). These residues
are not directly involved in receptor binding as a mutant substi-
tuting the cationic residues to alanine is still capable of receptor
activation and inducing cell migration in vitro. However, the
inability to cause these events in vivo demonstrates that GAG
binding is necessary for its physiological function. Affinities for
the GAG interaction can vary from KD’s in the nanomolar range
for the tight binding of CXCL11 to the mid-micromolar range
for many other chemokines (Severin et al., 2010; Laguri et al.,
2011).
GAG-bound chemokine complexes are difficult for high res-
olution structural studies due to the conformational plasticity
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of the GAGs and the aggregative tendencies of these mixtures,
however, there have been some recent successes. In NMR exper-
iments, the backbone amide peaks of CXCL8 could be followed
when hexamers of four different types of GAGs were titrated
into separate samples (Pichert et al., 2012). No major chem-
ical shift perturbations were seen in titrations with hyaluro-
nan, which has one carboxylate group in every repeating disac-
charide unit, indicating that no major structural changes take
place in CXCL8. Chemical shift perturbations were seen, how-
ever, in titrations with dermatan sulfate, chondroitin-4-sulfate
and chondroitin-6-sulfate. The areas affected involved residues
15–45, covering the end of the N-terminal fragment and the
first two β-strands, and most significantly residues 57–77 in
the α-helix. In addition to causing large shifts for the basic
residues in the α-helix, the movement of the Glu75 amide peak
reflects an electrostatic repulsion between this residue and the
sulfate groups. Molecular docking of a chondroitin-6-sulfate
hexasaccharide onto the CXCL8 dimer shows that the GAG
molecule can become sandwiched and act as a bridge for the α-
helices of the two subunits that run antiparallel to each other
(Figure 5A).
Using a 13C-labeled heparan sulfate analog, Laguri and
coworkers were also able to obtain structural information for both
partners in the complex of CXCL12 bound to aGAG (Laguri et al.,
2011). NMR chemical shift perturbations confirmed that Arg12
and Lys24 are the basic residues most involved in the interac-
tion. This and other shift perturbation information was fed along
with NMR saturation transfer difference results into Haddock,
a data-driven molecular docking program (Dominguez et al.,
2003). The resulting energy minimized structures show quite a
different picture from the CXCL8 complex, with the octameric
GAG now running across the β-sheet of the CXCL12 dimer
on the opposite face of the α-helices (Figure 5B) (Laguri et al.,
2011).
In addition to GAG-releasing proteinases, some bacteria can
secrete proteolytic enzymes that directly modulate chemokine
activities. Enzymes secreted by different bacterial sources can
FIGURE 5 | Structural models of chemokine dimers bound to
glycosaminoglycans. (A) A chondroitin-6-sulfate hexasaccharide
sandwiched between the anti-parallel α-helices of the CXCL8 dimer (Pichert
et al., 2012). (B) A heparan sulfate octasaccharide analogue docked onto the
β-sheet of the CXCL12 dimer on the face of the protein that is opposite to
where the α-helices are located (Laguri et al., 2011).
cause different changes in a chemokine’s range of activity. For
example, the streptococcal cysteine proteinase SpeB is a viru-
lence factor released by S. pyogenes that degrades several AMPs
and several chemokines including CXCL10, CCL5, CCL20, and
XCL1 (Egesten et al., 2009). However, it has no activity toward
CXCL8 and CCL5. The 103 a.a. CXCL9 is partially digested
by SpeB and SufA, a proteinase released by the opportunis-
tic pathogen Finegoldia magna. CXCL9 is attacked at both
ends, losing a portion of the extended N-terminal loop and
residues past the α-helix at the C-terminus. The SpeB-digested
CXCL9 fragment loses its chemotactic activity, but it retains
activity against S. pyogenes. The SufA-digested CXCL9 frag-
ment loses activity against F. magna, however, remains antimi-
crobial towards S. pyogene. SufA also cleaves CXCL14/BRAK
(breast and kidney-expressed chemokine) at several sites through-
out its sequence and, although this attenuates the activities
of CXCL14 against both S. pyogenes and F. magna, killing
activity for the latter bacterium is lost much faster than for
the former (Frick et al., 2011). Adding to the survival mech-
anism against chemokines, F. magna and S. pyogenes can
secrete FAF (F. magna adhesion factor) and SIC (streptococ-
cal inhibitor of complement), respectively, which directly bind
to CXCL14 and CXCL9 to inactivate them without a need for
proteolysis.
Bacteria also have ways of using host chemokines to their
advantage. For example, MRSA release the virulence factor SPA
(S. aureus protein A) upon being presented with a majority
of chemokines (Yung et al., 2011). This occurs through direct
chemokine interactions with MRSA at low bacterial densities,
however, the molecular mechanisms leading to SPA release are
currently unknown. Furthermore, whether or not a chemokine
can induce the release of SPA does not seem to be related to its
anti-MRSA activity.
Finally, a specific target has been suggested as part of the
antimicrobial mechanism of CXCL10. This protein was identified
in B. anthracis as FtsX, the transmembrane domain of a putative
ATP-binding cassette transporter (Crawford et al., 2011). When
incubated with an FtsX-deletion mutant strain of B. anthracis,
CXCL10 is unable to localize to the cell membrane, thereby con-
ferring resistance to the bacterium. FtsX is well conserved inmany
bacteria and so it could be an important molecular target for
other chemokines and perhaps for some AMPs as well.
CONCLUDING REMARKS
Chemokines have long been known for their roles in homeostasis
and they play a major role during times of inflammation
in the human body (Zlotnik and Yoshie, 2012). Their sec-
ondary ability to directly kill microbes was discovered only a
decade ago and currently, at least some degree of antimicro-
bial activity has been found for nearly all human chemokines.
While some may argue that these results may not hold much
weight outside of the forgiving conditions that can be cre-
ated inside the laboratory, this secondary “moonlighting” func-
tion seems crucial for the immune system in vivo (Wolf and
Moser, 2012). Much like AMPs, these chemokines have a large
cationic surface to promote electrostatic interactions with bac-
terial surfaces while keeping them harmless to eukaryotic cells.
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The antimicrobial activity can be modulated by partial digestion,
conformational rearrangements, self-association, and through
molecular interactions, particularly with GAGs. The structural
features that are responsible for distinguishing the potency and
range of activity of one chemokine from another is still unclear.
To gain a better understanding of their behavior in vivo, future
structural work in the chemokine research field should take
into account their antimicrobial functions in addition to their
signaling activities.
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